Mei-Li Wen

2.0k total citations
17 papers, 333 citations indexed

About

Mei-Li Wen is a scholar working on Oncology, Genetics and Hematology. According to data from OpenAlex, Mei-Li Wen has authored 17 papers receiving a total of 333 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Oncology, 6 papers in Genetics and 6 papers in Hematology. Recurrent topics in Mei-Li Wen's work include Chronic Lymphocytic Leukemia Research (6 papers), Cancer Treatment and Pharmacology (6 papers) and Chronic Myeloid Leukemia Treatments (6 papers). Mei-Li Wen is often cited by papers focused on Chronic Lymphocytic Leukemia Research (6 papers), Cancer Treatment and Pharmacology (6 papers) and Chronic Myeloid Leukemia Treatments (6 papers). Mei-Li Wen collaborates with scholars based in United States, Germany and China. Mei-Li Wen's co-authors include David Kan, Stephen Castaneda, Kelly McGlinchey, Francis Y. Lee, Ivan Inigo, Robert A. Kramer, Amy Camuso, Krista Fager, Christine Flefleh and Richard Smykla and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer Research.

In The Last Decade

Mei-Li Wen

17 papers receiving 328 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Mei-Li Wen United States	9	166	120	109	94	84	17	333
Amy Camuso United States	9	162 1.0×	163 1.4×	114 1.0×	113 1.2×	84 1.0×	12	402
Krista Fager United States	8	161 1.0×	135 1.1×	114 1.0×	113 1.2×	84 1.0×	11	374
Jeffrey Keats United States	8	165 1.0×	156 1.3×	118 1.1×	185 2.0×	92 1.1×	12	402
Sarah Pope United States	4	155 0.9×	154 1.3×	100 0.9×	207 2.2×	77 0.9×	5	506
Roberta Rostagno Italy	5	284 1.7×	93 0.8×	227 2.1×	121 1.3×	142 1.7×	6	464
Sujata Chakraborty United States	10	272 1.6×	94 0.8×	146 1.3×	286 3.0×	57 0.7×	17	541
Daisy Moreno United States	7	201 1.2×	61 0.5×	174 1.6×	178 1.9×	54 0.6×	9	430
Pekka Anttila Finland	12	261 1.6×	129 1.1×	132 1.2×	244 2.6×	36 0.4×	31	404
Mutiah Apatira United States	6	225 1.4×	95 0.8×	174 1.6×	145 1.5×	15 0.2×	8	410
M Collyn-d'Hooghe France	8	42 0.3×	98 0.8×	91 0.8×	166 1.8×	32 0.4×	15	364

Countries citing papers authored by Mei-Li Wen

Since Specialization

Citations

This map shows the geographic impact of Mei-Li Wen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mei-Li Wen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mei-Li Wen more than expected).

Fields of papers citing papers by Mei-Li Wen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mei-Li Wen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mei-Li Wen. The network helps show where Mei-Li Wen may publish in the future.

Co-authorship network of co-authors of Mei-Li Wen

This figure shows the co-authorship network connecting the top 25 collaborators of Mei-Li Wen. A scholar is included among the top collaborators of Mei-Li Wen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mei-Li Wen. Mei-Li Wen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

17 of 17 papers shown

Wen, Mei-Li, et al.. (2025). Yiqi Huayu Jiedu Decoction reduces colorectal cancer liver metastasis by promoting N1 neutrophil chemotaxis. Frontiers in Immunology. 16. 1530053–1530053. 1 indexed citations

Lewin, Anne, Mei-Li Wen, Rolf-Peter Ryseck, et al.. (2009). Antiangiogenic (AG) Synergy with Ixabepilone (IXA): Translation of Preclinical Studies to the Clinical Setting.. Cancer Research. 69(24_Supplement). 206–206. 5 indexed citations

Vite, Gregory D., Iontcho R. Vlahov, Steven Howard, et al.. (2008). Synthesis and in vitro effects of BMS-753493, an epothilone-folate conjugate designed to selectively target FR expressing tumor cells. Cancer Research. 68. 4155–4155. 2 indexed citations

Shen, Han, Mei-Li Wen, Kelly L. Covello, et al.. (2008). Ixabepilone overcomes multiple mechanisms of drug resistance including overexpression of class III |i tubulin and breast cancer resistance protein. European Journal of Cancer Supplements. 6(7). 219–220. 7 indexed citations

Lee, Francis Y. F., Kelly L. Covello, Stephen Castaneda, et al.. (2008). Synergistic Antitumor Activity of Ixabepilone (BMS-247550) Plus Bevacizumab in Multiple In vivo Tumor Models. Clinical Cancer Research. 14(24). 8123–8131. 37 indexed citations

Covello, Kelly L., Christine Flefleh, Krista Menard, et al.. (2008). Preclinical pharmacology of epothilone-folate conjugate BMS-753493, a tumor-targeting agent selected for clinical development. 68. 2326–2326. 8 indexed citations

Luo, Feng, Yu Chen Barrett, Zheng Yang, et al.. (2008). Identification and validation of phospho-SRC, a novel and potential pharmacodynamic biomarker for dasatinib (SPRYCEL™), a multi-targeted kinase inhibitor. Cancer Chemotherapy and Pharmacology. 62(6). 1065–1074. 43 indexed citations

Kellar, Kristen A., Matthew V. Lorenzi, Dan You, et al.. (2006). Constitutively active receptor tyrosine kinases as oncogenes in preclinical models for cancer therapeutics. Molecular Cancer Therapeutics. 5(6). 1571–1576. 5 indexed citations

Luo, Feng, Zheng Yang, Amy Camuso, et al.. (2006). Dasatinib (BMS-354825) Pharmacokinetics and Pharmacodynamic Biomarkers in Animal Models Predict Optimal Clinical Exposure. Clinical Cancer Research. 12(23). 7180–7186. 113 indexed citations

10.

Lee, Francis Y., Louis J. Lombardo, Amy Camuso, et al.. (2005). BMS-354825 potently inhibits multiple selected oncogenic tyrosine kinases and possesses broad-spectrum antitumor activities in vitro and in vivo. Cancer Research. 65. 159–159. 38 indexed citations

11.

Lee, Francis Y., Mei-Li Wen, Rajeev S. Bhide, et al.. (2005). Dasatinib (BMS-354825) Overcomes Multiple Mechanisms of Imatinib Resistance in Chronic Myeloid Leukemia (CML).. Blood. 106(11). 1994–1994. 14 indexed citations

12.

Lee, Francis Y., Mei-Li Wen, Amy Camuso, et al.. (2005). Quiescent Chronic Myelogenous Leukemia (CML) Cells Are Resistant to BCR-ABL Inhibitors but Preferentially Sensitive to BMS-214662, a Farnesyltransferase Inhibitor (FTI) with Unique Quiescent-Cell Selective Cytotoxicity.. Blood. 106(11). 1993–1993. 5 indexed citations

13.

Castaneda, Stephen, Ivan Inigo, David Kan, et al.. (2005). Ixabepilone (BMS-247550) plus trastuzumab combination chemotherapy induces synergistic antitumor efficacy in HER2 dependent breast cancers and is accompanied by modulation of molecular response markers. Journal of Clinical Oncology. 23(16_suppl). 561–561. 26 indexed citations

14.

Lee, Francis Y., Louis J. Lombardo, R. M. Borzilleri, et al.. (2004). Pharmacodynamic analysis of target inhibition and tumor endothelial cell death in biopsies obtained from patients treated with the VEGF receptor antagonists SU5416 or SU6668. Cancer Research. 64. 921–921. 3 indexed citations

15.

Luo, Feng, Zheng Yang, Amy Camuso, et al.. (2004). Pharmacokinetics- and Pharmacodynamics-Guided Optimization of the Dose and Treatment Schedule for the Dual SRC/ABL Inhibitor BMS-354825.. Blood. 104(11). 1987–1987. 1 indexed citations

16.

Wild, Robert A., Stephen Castaneda, Christine Flefleh, et al.. (2004). BMS-354825, a Dual SRC/ABL Kinase Inhibitor, Displays Potent Anti-Tumor Activity in a Model of Intracranial CML Growth.. Blood. 104(11). 1988–1988. 9 indexed citations

17.

Alvarez, Vernon L., et al.. (1986). Site-specifically modified 111In labelled antibodies give low liver backgrounds and improved radioimmunoscintigraphy. International Journal of Radiation Applications and Instrumentation Part B Nuclear Medicine and Biology. 13(4). 347–352. 16 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact